Canopy Growth Corporation
$1.2
▲
2.63%
2026-04-21 06:00:00
www.canopygrowth.com
NMS: CGC
Explore Canopy Growth Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$709.79 M
Current Price
$1.2
52W High / Low
$3.28 / $1.18
Stock P/E
—
Book Value
$1.49
Dividend Yield
—
ROCE
-8.06%
ROE
-48.5%
Face Value
—
EPS
$-1.34
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
960
Beta
2.32
Debt / Equity
33.65
Current Ratio
5.34
Quick Ratio
2.1
Forward P/E
-14.37
Price / Sales
1.69
Enterprise Value
$280.4 M
EV / EBITDA
-32.08
EV / Revenue
1.01
Rating
Hold
Target Price
$1.77
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Incannex Healthcare Inc. | $3.84 | — | $51 M | — | — | -1.3% | $49.8 / $2.4 | $6.13 |
| 2. | Harrow, Inc. | $40.5 | — | $1.51 B | — | 10.06% | -8.47% | $54.85 / $21.12 | $1.41 |
| 3. | InMed Pharmaceuticals Inc. | $0.72 | — | $2.4 M | — | -57.63% | -97.2% | $7.98 / $0.57 | $3.42 |
| 4. | Neurocrine Biosciences, Inc. | $130.77 | 28.05 | $13.18 B | — | 16.37% | 16.38% | $160.18 / $98.95 | $32.5 |
| 5. | Cumberland Pharmaceuticals Inc. | $3.15 | — | $47.57 M | — | -6.97% | -12.17% | $6.27 / $1.85 | $1.66 |
| 6. | China SXT Pharmaceuticals, Inc. | $2.06 | — | $1.97 M | — | -17.13% | -50.3% | $1,046.98 / $1.25 | $26.16 |
| 7. | Amphastar Pharmaceuticals, Inc. | $22.92 | 10.43 | $1.02 B | — | 9.54% | 12.9% | $31.26 / $17.03 | $17.28 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 74.54 M | 66.68 M | 72.13 M | 65.03 M | 74.76 M | — |
| Operating Profit | -13.1 M | -14.67 M | -17.86 M | -4.39 M | -19.5 M | — |
| Net Profit | -62.63 M | -1.64 M | -41.53 M | -220.79 M | -121.9 M | — |
| EPS in Rs | -0.15 | -0 | -0.1 | -0.52 | -0.29 | -1.48 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 269 M | 297.15 M | 333.25 M | 475.7 M |
| Operating Profit | -66.39 M | -127.96 M | -395.78 M | -638.49 M |
| Net Profit | -598.12 M | -657.27 M | -3.28 B | -310.04 M |
| EPS in Rs | -1.41 | -1.55 | -7.75 | -0.73 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 917.7 M | 1.3 B | 2.44 B | 5.61 B |
| Total Liabilities | 430.49 M | 799.82 M | 1.68 B | 1.98 B |
| Equity | 487.21 M | 500.37 M | 758.43 M | 3.58 B |
| Current Assets | 294.57 M | 371.18 M | 1.08 B | 1.73 B |
| Current Liabilities | 94.4 M | 234.72 M | 803.84 M | 213.19 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -165.75 M | -281.95 M | -557.55 M | -545.81 M |
| Investing CF | -47.79 M | 241.59 M | 433.38 M | 230.82 M |
| Financing CF | 148.66 M | -465.06 M | -19.69 M | -45.53 M |
| Free CF | -177.03 M | -285.95 M | -568 M | -593.92 M |
| Capex | -11.28 M | -4 M | -10.45 M | -48.11 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -9.47% | -10.83% | -29.94% | — |
| Earnings Growth % | 9% | 79.95% | -957.32% | — |
| Profit Margin % | -222.35% | -221.19% | -983.68% | -65.18% |
| Operating Margin % | -24.68% | -43.06% | -118.76% | -134.22% |
| Gross Margin % | 29.56% | 27.22% | -19.06% | -39.4% |
| EBITDA Margin % | -178.19% | -105.28% | -864.2% | -11.14% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-12-20 | 1:0.1 |